Palmer C S, Schmier J K, Snyder E, Scott B
MEDTAP International, Bethesda, Maryland 20814, USA.
Qual Life Res. 2000;9(7):819-27. doi: 10.1023/a:1008903126315.
The purpose of this study was to derive patient preferences and utilities for outcomes associated with treatment of motor fluctuations, or 'off-time', for patients with Parkinson's disease (PD). Visual analog scale (VAS) and standard gamble (SG) approaches were used with 60 patients to determine patient preferences and utilities for 10 health state descriptions. Health state descriptions were categorized according to two factors: disease severity, and proportion of the day with 'off-time'. There were two representative levels of disease severity, based on Hoehn and Yahr stages 1.5 and 2.5: unilateral disease with no postural instability, and bilateral disease with some postural instability. These severity levels were combined with five levels of 'off-time' per day ranging from none to > 75% of the day. Patients' mean preference or utility for their own current health ranged from 0.65 +/- 0.20 (VAS) to 0.74 +/- 0.22 (SG). Patients assigned the lowest mean values to the health state description for Hoehn and Yahr stage 2.5 with 'off-time' for > 75% of the day (VAS: 0.17 +/- 0.17; SG: 0.49 +/- 0.27). The highest mean values were assigned to Hoehn and Yahr stage 1.5 with no 'off-time' (VAS: 0.83 +/- 0.17; SG: 0.85 +/- 0.18). The results of this study indicated patients with PD would likely seek treatment that would minimize the amount of 'off-time' experienced per day, and that patients were relatively risk averse.
本研究的目的是得出帕金森病(PD)患者对于与运动波动(即“关期”)治疗相关结局的偏好和效用值。对60名患者采用视觉模拟量表(VAS)和标准博弈法(SG),以确定患者对10种健康状态描述的偏好和效用值。健康状态描述根据两个因素进行分类:疾病严重程度和“关期”占一天的比例。基于Hoehn和Yahr分期的1.5期和2.5期,有两个具有代表性的疾病严重程度水平:无姿势不稳的单侧疾病,以及有一定姿势不稳的双侧疾病。这些严重程度水平与每天从无到超过一天75%的五个“关期”水平相结合。患者对自身当前健康状况的平均偏好或效用值范围为0.65±0.20(VAS)至0.74±0.22(SG)。患者对Hoehn和Yahr 2.5期且“关期”超过一天75%的健康状态描述赋予了最低平均值(VAS:0.17±0.17;SG:0.49±0.27)。最高平均值赋予了Hoehn和Yahr 1.5期且无“关期”的情况(VAS:0.83±0.17;SG:0.85±0.18)。本研究结果表明,PD患者可能会寻求能使每天经历的“关期”量最小化的治疗,并且患者相对厌恶风险。